Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Clavis Pharma
Woman and Man Max 99 years
Clavis Pharma ASA
Update Il y a 4 ans
A multicentre, dose finding, phase II Study of CP-4055 in combination with Sorafenib in patients with metastatic malignant melanoma
To evaluate the objective tumour response in patients with metastatic malignt melanoma when treated with CP-4055 for infusion D1-5/4w in combination with sorafenib
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Clavis Pharma ASA
Update Il y a 4 ans
A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer
To evaluate the objective tumour response in patients with advanced colorectal cancer when treated with CP-4055 for infusion D1-5/4w.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Clavis Pharma ASA
Update Il y a 4 ans
A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia
1. Estimate rate of complete remission (CR), including complete remission except for platelet count < 100 x 109/L (CRp) (CR + CRp rate) in patients with AML who have not attained blast clearance after...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Clavis Pharma as
Update Il y a 4 ans
A phase II Clinical Study of CP-4055 in patients with metastatic melanoma not previous treated with chemotherapy
To evaluate the objective tumour response in chemotherapy-naive patients with metastatic melanoma when treated with CP-4055 for infusion D1-5/4w.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Clavis Pharma ASA
Update Il y a 4 ans
A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer
Phase I: To determine the recommended dose of CP-4055 when given five consecutive days twice in a 4 week schedule, D1-5 and D8(+2)-12 (+2) q4W Phase II: To determine the antitumour activity of CP-405...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Clavis Pharma ASA
Update Il y a 4 ans
A Phase I/II Study of CP-4055 in Patients with Refractory/Relapsed Hematologic Malignancies
Phase II : Determine the efficacy of single agent CP-4055 in patients receiving second salvage therapy for AML
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Clavis Pharma
Update Il y a 4 ans
CLAVELA : Essai de phase 3 randomisé visant à évaluer l’efficacité et la tolérance de l’élacytarabine en comparaison avec un traitement recommandé par l’investigateur, chez des patients ayant une leucémie myéloïde aiguë de stade avancé. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité de l’élacytarabine, chez les patients ayant une leucémie aigüe de stade avancé. Les patients seront répartis de façon aléatoire en deux groupes de t...
Country
France
organs
Leucémies aiguës
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Clavis Pharma
Update Il y a 4 ans
Clavis CP4055-106 : Essai de phase 1-2 en escalade de dose, évaluant l’efficacité et la tolérance d’un traitement par CP-4055 chez des patients ayant une tumeur hématologique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de l’essai est d’évaluer l’efficacité et la tolérance d’un traitement par CP-4055 chez des patients ayant une tumeur hématologique. Les patients inclus dans la phase 1 seront réparties en ...
Country
France
organs
Tout cancer hématologique
,
Leucémies aiguës
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Clavis Pharma ASA
Update Il y a 4 ans
A phase II study of CP-4126 in patients with advanced pancreatic cancer
The main objective is to assess the biological activity of CP-4126 in patients with advanced pancreatic cancer.
Country
None
organs
None
Specialty
None
Closed trial
More information